Last reviewed · How we verify
Regimen 2, Course, 1, Cycle C1
Regimen 2, Course, 1, Cycle C1 is a Small molecule drug developed by Baylor College of Medicine. It is currently in Phase 1 development.
At a glance
| Generic name | Regimen 2, Course, 1, Cycle C1 |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma (PHASE2)
- Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
- HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML (PHASE2)
- Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regimen 2, Course, 1, Cycle C1 CI brief — competitive landscape report
- Regimen 2, Course, 1, Cycle C1 updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI
Frequently asked questions about Regimen 2, Course, 1, Cycle C1
What is Regimen 2, Course, 1, Cycle C1?
Regimen 2, Course, 1, Cycle C1 is a Small molecule drug developed by Baylor College of Medicine.
Who makes Regimen 2, Course, 1, Cycle C1?
Regimen 2, Course, 1, Cycle C1 is developed by Baylor College of Medicine (see full Baylor College of Medicine pipeline at /company/baylor-college-of-medicine).
What development phase is Regimen 2, Course, 1, Cycle C1 in?
Regimen 2, Course, 1, Cycle C1 is in Phase 1.